Jean-Frederic Viret Sells 3,159 Shares of Coherus Biosciences Inc (NASDAQ:CHRS) Stock

Coherus Biosciences Inc (NASDAQ:CHRS) CFO Jean-Frederic Viret sold 3,159 shares of Coherus Biosciences stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $19.59, for a total transaction of $61,884.81. Following the transaction, the chief financial officer now owns 6,462 shares in the company, valued at approximately $126,590.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Jean-Frederic Viret also recently made the following trade(s):

  • On Monday, November 18th, Jean-Frederic Viret sold 3,112 shares of Coherus Biosciences stock. The stock was sold at an average price of $18.88, for a total transaction of $58,754.56.
  • On Friday, October 18th, Jean-Frederic Viret sold 1,388 shares of Coherus Biosciences stock. The stock was sold at an average price of $19.02, for a total transaction of $26,399.76.
  • On Wednesday, October 16th, Jean-Frederic Viret sold 3,159 shares of Coherus Biosciences stock. The stock was sold at an average price of $19.00, for a total transaction of $60,021.00.
  • On Monday, September 23rd, Jean-Frederic Viret sold 740 shares of Coherus Biosciences stock. The shares were sold at an average price of $21.78, for a total transaction of $16,117.20.
  • On Wednesday, September 18th, Jean-Frederic Viret sold 3,159 shares of Coherus Biosciences stock. The shares were sold at an average price of $20.44, for a total transaction of $64,569.96.

CHRS stock traded up $0.33 during midday trading on Friday, hitting $18.82. The stock had a trading volume of 525,643 shares, compared to its average volume of 987,626. The firm has a market cap of $1.38 billion, a P/E ratio of -5.84 and a beta of 2.90. The company has a current ratio of 3.34, a quick ratio of 3.25 and a debt-to-equity ratio of 3.37. Coherus Biosciences Inc has a 1-year low of $8.32 and a 1-year high of $23.91. The business has a fifty day moving average price of $18.69 and a two-hundred day moving average price of $19.41.

Coherus Biosciences (NASDAQ:CHRS) last announced its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.36 by $0.27. The company had revenue of $111.68 million for the quarter, compared to analyst estimates of $93.58 million. On average, equities analysts anticipate that Coherus Biosciences Inc will post 1.15 EPS for the current year.

Several equities analysts recently issued reports on CHRS shares. Credit Suisse Group restated a “buy” rating and issued a $36.00 target price on shares of Coherus Biosciences in a report on Friday, November 8th. BidaskClub lowered shares of Coherus Biosciences from a “hold” rating to a “sell” rating in a report on Wednesday, October 16th. Citigroup boosted their target price on shares of Coherus Biosciences from $27.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Mizuho set a $43.00 target price on shares of Coherus Biosciences and gave the company a “buy” rating in a report on Sunday, September 29th. Finally, Barclays set a $31.00 target price on shares of Coherus Biosciences and gave the company a “buy” rating in a report on Monday, August 12th. Two research analysts have rated the stock with a sell rating and eight have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $30.38.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. raised its holdings in shares of Coherus Biosciences by 10.6% during the second quarter. BlackRock Inc. now owns 5,037,431 shares of the biotechnology company’s stock valued at $111,327,000 after purchasing an additional 483,541 shares during the period. Vanguard Group Inc. raised its holdings in shares of Coherus Biosciences by 3.0% during the second quarter. Vanguard Group Inc. now owns 2,958,583 shares of the biotechnology company’s stock valued at $65,384,000 after purchasing an additional 87,091 shares during the period. Rock Springs Capital Management LP raised its holdings in shares of Coherus Biosciences by 180.6% during the second quarter. Rock Springs Capital Management LP now owns 1,880,000 shares of the biotechnology company’s stock valued at $41,548,000 after purchasing an additional 1,210,000 shares during the period. Nuveen Asset Management LLC acquired a new position in shares of Coherus Biosciences during the second quarter valued at about $25,695,000. Finally, C WorldWide Group Holding A S raised its holdings in shares of Coherus Biosciences by 19.2% during the third quarter. C WorldWide Group Holding A S now owns 808,464 shares of the biotechnology company’s stock valued at $16,379,000 after purchasing an additional 130,000 shares during the period. Hedge funds and other institutional investors own 97.45% of the company’s stock.

Coherus Biosciences Company Profile

Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.

Featured Article: Sell-Side Analysts

Insider Buying and Selling by Quarter for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.